Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $20.62 Consensus Target Price from Brokerages

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have received a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.6250.

A number of research firms recently weighed in on VIR. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Leerink Partners raised their price objective on Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating on shares of Vir Biotechnology in a research report on Monday, August 10th. Morgan Stanley set a $25.00 target price on Vir Biotechnology in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Janet Napolitano sold 3,200 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Vir Biotechnology

Institutional investors have recently modified their holdings of the stock. Fiduciary Financial Advisors purchased a new stake in shares of Vir Biotechnology during the second quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vir Biotechnology by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after purchasing an additional 1,390 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Vir Biotechnology in the 2nd quarter valued at about $35,000. UMB Bank n.a. boosted its holdings in Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after buying an additional 6,597 shares during the last quarter. Finally, CWM LLC boosted its holdings in Vir Biotechnology by 23.0% in the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock worth $53,000 after buying an additional 1,646 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock opened at $9.39 on Tuesday. The firm has a 50-day simple moving average of $9.32 and a two-hundred day simple moving average of $9.14. The company has a market cap of $1.59 billion, a P/E ratio of -5.05 and a beta of 1.66. Vir Biotechnology has a fifty-two week low of $4.25 and a fifty-two week high of $11.66.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The firm had revenue of $238.95 million for the quarter, compared to analysts’ expectations of $135.88 million. During the same period last year, the firm earned ($0.80) EPS. The company’s quarterly revenue was up 19582.5% on a year-over-year basis. Equities research analysts forecast that Vir Biotechnology will post -1.84 EPS for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.